Shares of Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) have received a consensus recommendation of “Hold” from the fifteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and seven have given a buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $85.3636.
A number of research analysts recently issued reports on the stock. JPMorgan Chase & Co. decreased their price objective on shares of Tempus AI from $85.00 to $80.00 and set a “neutral” rating for the company in a report on Monday. TD Cowen cut shares of Tempus AI from a “buy” rating to a “hold” rating and set a $88.00 price target for the company. in a report on Tuesday, October 21st. BTIG Research increased their price objective on shares of Tempus AI from $96.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, November 25th. HC Wainwright dropped their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Needham & Company LLC upped their target price on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th.
Read Our Latest Research Report on TEM
Insider Buying and Selling
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Tempus AI by 22.1% during the 3rd quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock worth $762,032,000 after buying an additional 1,706,837 shares in the last quarter. Voloridge Investment Management LLC increased its position in shares of Tempus AI by 183.0% in the third quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock valued at $129,708,000 after acquiring an additional 1,039,176 shares during the last quarter. Franklin Resources Inc. increased its position in shares of Tempus AI by 0.4% in the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock valued at $117,523,000 after acquiring an additional 5,375 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in Tempus AI by 312.7% during the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after acquiring an additional 965,730 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in Tempus AI by 6.4% during the third quarter. AQR Capital Management LLC now owns 904,872 shares of the company’s stock valued at $73,032,000 after purchasing an additional 54,692 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.
Tempus AI Trading Down 2.7%
Shares of NASDAQ TEM opened at $68.67 on Tuesday. The company has a market cap of $12.22 billion, a PE ratio of -57.71 and a beta of 5.00. Tempus AI has a 1-year low of $31.36 and a 1-year high of $104.32. The company has a current ratio of 3.28, a quick ratio of 3.12 and a debt-to-equity ratio of 2.45. The company has a 50-day moving average of $80.48 and a two-hundred day moving average of $73.69.
Tempus AI (NASDAQ:TEM – Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. Tempus AI had a negative return on equity of 73.21% and a negative net margin of 18.45%.The business had revenue of $334.21 million for the quarter, compared to analysts’ expectations of $328.89 million. During the same quarter last year, the business earned ($0.46) earnings per share. The firm’s quarterly revenue was up 84.7% compared to the same quarter last year. As a group, equities analysts expect that Tempus AI will post -6.15 earnings per share for the current fiscal year.
Tempus AI Company Profile
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
See Also
- Five stocks we like better than Tempus AI
- The How And Why of Investing in Oil Stocks
- ServiceNow’s $7 Billion Gamble: Panic or Opportunity?
- What Are Earnings Reports?
- Dell and HP Are Raising Prices—And Investors Should Take Note
- What Are the FAANG Stocks and Are They Good Investments?
- Why DLocal Is the Top Emerging Market Fintech Stock to Watch for 2026
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
